Veregen sinecatechins regulatory update

MediGene said Switzerland approved Veregen to treat genital warts. The topical formulation of polyphenols extracted from green tea leaves is already approved in the U.S., Germany, Austria and Spain. Solvay Pharmaceuticals, a unit of Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.), has rights to Veregen in Germany, Austria and Switzerland, and expects to launch the product in Switzerland this year. Juste S.A.Q.F. (Madrid, Spain) has exclusive rights to market Veregen in Spain, where the company plans to launch it this half. ...